Papers
Topics
Authors
Recent
Gemini 2.5 Flash
Gemini 2.5 Flash
184 tokens/sec
GPT-4o
7 tokens/sec
Gemini 2.5 Pro Pro
45 tokens/sec
o3 Pro
4 tokens/sec
GPT-4.1 Pro
38 tokens/sec
DeepSeek R1 via Azure Pro
28 tokens/sec
2000 character limit reached

Multi-objective Molecular Optimization for Opioid Use Disorder Treatment Using Generative Network Complex (2306.07484v1)

Published 13 Jun 2023 in cs.LG and q-bio.BM

Abstract: Opioid Use Disorder (OUD) has emerged as a significant global public health issue, with complex multifaceted conditions. Due to the lack of effective treatment options for various conditions, there is a pressing need for the discovery of new medications. In this study, we propose a deep generative model that combines a stochastic differential equation (SDE)-based diffusion modeling with the latent space of a pretrained autoencoder model. The molecular generator enables efficient generation of molecules that are effective on multiple targets, specifically the mu, kappa, and delta opioid receptors. Furthermore, we assess the ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties of the generated molecules to identify drug-like compounds. To enhance the pharmacokinetic properties of some lead compounds, we employ a molecular optimization approach. We obtain a diverse set of drug-like molecules. We construct binding affinity predictors by integrating molecular fingerprints derived from autoencoder embeddings, transformer embeddings, and topological Laplacians with advanced machine learning algorithms. Further experimental studies are needed to evaluate the pharmacological effects of these drug-like compounds for OUD treatment. Our machine learning platform serves as a valuable tool in designing and optimizing effective molecules for addressing OUD.

Definition Search Book Streamline Icon: https://streamlinehq.com
References (47)
  1. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. Jama, 284(13):1689–1695, 2000.
  2. Medications for substance use disorders. Social work in public health, 28(3-4):264–278, 2013.
  3. Pharmacological and behavioral treatment of opioid use disorder. Psychiatric Research and Clinical Practice, 1(1):4–15, 2019.
  4. Shaocheng Wang. Historical review: opiate addiction and opioid receptors. Cell transplantation, 28(3):233–238, 2019.
  5. Effect of methadone maintenance treatment on heroin craving, a literature review. Journal of addictive diseases, 30(1):27–38, 2010.
  6. Buprenorphine treatment of opioid dependence: a review. Experimental and Clinical Psychopharmacology, 3(4):477, 1995.
  7. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a united states commercially insured population. Journal of substance abuse treatment, 85:90–96, 2018.
  8. Principles of early drug discovery. British journal of pharmacology, 162(6):1239–1249, 2011.
  9. Estimation of the size of drug-like chemical space based on gdb-17 data. Journal of computer-aided molecular design, 27:675–679, 2013.
  10. Adaptation of high-throughput screening in drug discovery—toxicological screening tests. International journal of molecular sciences, 13(1):427–452, 2011.
  11. The use of machine learning modeling, virtual screening, molecular docking, and molecular dynamics simulations to identify potential vegfr2 kinase inhibitors. Scientific Reports, 12(1):18825, 2022.
  12. Quantum machine learning framework for virtual screening in drug discovery: a prospective quantum advantage. Machine Learning: Science and Technology, 4(1):015023, 2023.
  13. Automatic chemical design using a data-driven continuous representation of molecules. ACS central science, 4(2):268–276, 2018.
  14. Deep learning approaches for de novo drug design: An overview. Current Opinion in Structural Biology, 72:135–144, 2022.
  15. Generating focused molecule libraries for drug discovery with recurrent neural networks. ACS central science, 4(1):120–131, 2018.
  16. Generative network complex (gnc) for drug discovery. Communications in information and systems, 19(3):241, 2019.
  17. A de novo molecular generation method using latent vector based generative adversarial network. Journal of Cheminformatics, 11(1):1–13, 2019.
  18. Digress: Discrete denoising diffusion for graph generation. arXiv preprint arXiv:2209.14734, 2022.
  19. Permutation invariant graph generation via score-based generative modeling. In International Conference on Artificial Intelligence and Statistics, pages 4474–4484. PMLR, 2020.
  20. Graphgdp: Generative diffusion processes for permutation invariant graph generation. arXiv preprint arXiv:2212.01842, 2022.
  21. A survey on graph diffusion models: Generative ai in science for molecule, protein and material. arXiv preprint arXiv:2304.01565, 2023.
  22. Equivariant 3d-conditional diffusion models for molecular linker design. arXiv preprint arXiv:2210.05274, 2022.
  23. Structure-based drug design with equivariant diffusion models. arXiv preprint arXiv:2210.13695, 2022.
  24. Score-based generative modeling in latent space. Advances in Neural Information Processing Systems, 34:11287–11302, 2021.
  25. Learning continuous and data-driven molecular descriptors by translating equivalent chemical representations. Chemical science, 10(6):1692–1701, 2019.
  26. Efficient multi-objective molecular optimization in a continuous latent space. Chemical science, 10(34):8016–8024, 2019.
  27. Early identification of herg liability in drug discovery programs by automated patch clamp. Frontiers in pharmacology, 5:203, 2014.
  28. Comparability of mixed ic50 data–a statistical analysis. PloS one, 8(4):e61007, 2013.
  29. Generative network complex for the automated generation of drug-like molecules. Journal of chemical information and modeling, 60(12):5682–5698, 2020.
  30. Extracting predictive representations from hundreds of millions of molecules. The Journal of Physical Chemistry Letters, 12(44):10793–10801, 2021.
  31. Persistent spectral graph. International journal for numerical methods in biomedical engineering, 36(9):e3376, 2020.
  32. Virtual screening of drugbank database for herg blockers using topological laplacian-assisted ai models. Computers in Biology and Medicine, 153:106491, 2023.
  33. Are 2d fingerprints still valuable for drug discovery? Physical chemistry chemical physics, 22(16):8373–8390, 2020.
  34. Computational homology. Applied Mathematical Sciences, 157, 2004.
  35. Computing persistent homology. In Proceedings of the twentieth annual symposium on Computational geometry, pages 347–356, 2004.
  36. Admetlab 2.0: an integrated online platform for accurate and comprehensive predictions of admet properties. Nucleic Acids Research, 49(1):5–14, 2021.
  37. Admet evaluation in drug discovery: 15. accurate prediction of rat oral acute toxicity using relevance vector machine and consensus modeling. Journal of cheminformatics, 8:1–19, 2016.
  38. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews, 64:4–17, 2012.
  39. Autodock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry, 31(2):455–461, 2010.
  40. James Bell. Pharmacological maintenance treatments of opiate addiction. British journal of clinical pharmacology, 77(2):253–263, 2014.
  41. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane database of systematic reviews, (2), 2014.
  42. Differences in δ𝛿\deltaitalic_δ-and μ𝜇\muitalic_μ-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology, 33(3):653–665, 2008.
  43. Methadone: applied pharmacology and use as adjunctive treatment in chronic pain. Postgraduate medical journal, 80(949):654–659, 2004.
  44. Opioid-induced respiratory depression in humans: a review of pharmacokinetic–pharmacodynamic modelling of reversal. British Journal of Anaesthesia, 122(6):e168–e179, 2019.
  45. De novo design of κ𝜅\kappaitalic_κ-opioid receptor antagonists using a generative deep learning framework. bioRxiv, pages 2023–04, 2023.
  46. Towards better opioid antagonists using deep reinforcement learning. arXiv preprint arXiv:2004.04768, 2020.
  47. Predictive models to identify small molecule activators and inhibitors of opioid receptors. Journal of Chemical Information and Modeling, 61(6):2675–2685, 2021.

Summary

We haven't generated a summary for this paper yet.